Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
Scott KizyJing Li HuangSchelomo MarmorTodd M TuttleJane Yuet Ching HuiPublished in: Breast cancer research and treatment (2017)
For patients with ER-positive ILC, 8% were in the high-risk and 72% were in the intermediate-risk groups as per the TAILORx RS cutoffs. In the high-risk group, the RS predicted a lower 5-year BCSS. Adjuvant chemotherapy did not seem to confer a survival benefit for either the intermediate- or the high-risk cohorts.